– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead program afimetoran, a potential best-in-disease oral therapy for lupus, to complete Phase 2 trial in 2H 2026 before commencing pivotal development program – – Saqib Islam, Chief Executive Officer, leads established executive team with proven track record in drug development and global commercialization of first- and best-in-class medicines – – $300 milli ...